Biosimilars Drive Significant Reductions in Specialty Drug Spending

Biosimilars Drive Significant Reductions in Specialty Drug Spending

Biosimilars are expected to significantly reduce specialty drug expenditures, with projections indicating potential savings of up to 20%. This analysis explores the market impact, patient cost benefits, and strategic implications for the pharmaceutical industry. For BD teams and investors, how much do biosimilars cost relative to originator biologics — and what adoption thresholds must be met — are now the central valuation questions in specialty pharmacy.

Key Takeaways

• Biosimilars are projected to cut specialty drug spending by up to 20%, with broader estimates suggesting $54 billion in reduced direct biologic spending from 2017 to 2026 — roughly 3% of total biologic expenditure over that period.
• Specialty drug spending has surged 566.5% with a compounded annual growth rate of 23.5%, rising from 21.7% of total healthcare spending in 2012 to 71.1% in 2021 — despite representing just 6.2% of prescriptions.
• The BPCIA pathway was explicitly designed to introduce competition among biologic manufacturers through a shorter, lower-cost approval process.
• FDA approved a record 18 biosimilars for 8 reference products in 2024, surpassing the agency's 60th biosimilar approval milestone.
• Biosimilar reimbursement under the IRA's ASP+8% mechanism creates structural margin incentives for provider adoption, accelerating formulary uptake.

Why Is Specialty Drug Spending Growing So Rapidly?

Specialty drug spending has undergone a structural transformation that now defines the economics of American pharmacy benefits. According to research published in PubMed, specialty drug spending increased by 566.5%, with a compounded annual growth rate of 23.5%. The share of total spending on specialty drugs climbed from 21.7% in 2012 to 71.1% in 2021. By that same year, specialty drugs accounted for just 6.2% of prescriptions but consumed 71.1% of total spending — a concentration ratio without parallel in any other drug category.

The implication for payers and employers is stark. While only 1–2% of plan members typically use specialty drugs, those claims now account for over 50% of most employers' total pharmacy budgets. This asymmetry between prescription volume and cost burden has made specialty drug management the single most consequential line item in benefit design — and the primary target for cost-containment strategies heading into 2027.

How Are Biosimilars Containing Biologic Drug Costs?

The Biologics Price Competition and Innovation Act (BPCIA), enacted as part of the 2010 Patient Protection and Affordable Care Act, authorized the FDA to create a regulatory approval pathway for biosimilars — biologic drugs that are very similar to already approved reference biologics in terms of potency, safety, and efficacy, but manufactured by different companies. BPCIA's shorter, lower-cost approval pathway was designed explicitly to introduce competition among biologic manufacturers.

The early data supports the thesis. As of July 2017, three biosimilars had reached the U.S. market with two additional products FDA-approved but not yet launched. A RAND Corporation analysis estimated that biosimilars will reduce direct spending on biologic drugs by $54 billion from 2017 to 2026, or about 3% of total estimated biologic spending over the same period. More recent projections suggest biosimilars could cut specialty drug spend by approximately 20% by 2029, though that figure is contingent on adoption reaching roughly 80% — a threshold requiring coordinated action across payers, providers, and pharmacy benefit managers.

The FDA's own approval data signals accelerating momentum. CDER approved a record 18 biosimilars for 8 reference products in 2024, more than any previous year, and surpassed the agency's 60th biosimilar approval milestone. This expanding approval pipeline gives payers more tools to drive formulary competition — and gives BD teams a growing set of partnership and acquisition targets to evaluate.

How Much Do Biosimilars Save Patients Out-of-Pocket?

The patient-level financial impact of biosimilar adoption is measurable and meaningful. Patients who switched to biosimilars paid significantly less out-of-pocket than those who remained on reference biologics. For infliximab biosimilars, average savings reached approximately 12% — roughly $300 per patient. For filgrastim, the savings were more dramatic: approximately 45%, or about $600 per patient.

These figures carry weight beyond individual budgets. Lower out-of-pocket costs correlate with improved adherence — a variable that directly affects outcomes in chronic inflammatory and oncologic conditions where biologics are standard of care. For analysts modeling the total cost of care, the adherence dividend from biosimilar adoption represents a secondary savings layer that compounds the direct price reduction.

Are Biosimilars as Safe and Effective as Reference Biologics?

A persistent question among clinicians and formulary committees concerns the comparability of biosimilars to their reference products. Biosimilars are not identical to their reference biologics. As detailed in a PMC review, they are "similar, but not identical, to their reference drug, meaning that they may have small differences that could potentially affect both safety and efficacy." This distinction matters analytically — biosimilars are not small-molecule generics, and their regulatory pathway reflects that complexity.

That said, the FDA's approval framework requires demonstration of analytical, clinical, and non-clinical comparability. The agency evaluates structural and functional characterization, animal studies, and clinical immunogenicity data before licensure. The practical result is that marketed biosimilars have demonstrated no clinically meaningful differences from their reference products in the indications studied — a track record that has supported growing acceptance among specialists and payers alike. The FDA's Part 15 hearing transcripts on biosimilars provide additional detail on the evidentiary standards applied during review.

What Drives Biosimilar Reimbursement and Market Adoption?

The reimbursement architecture for biosimilars has evolved to accelerate adoption. Effective October 1, 2022, a "qualifying biosimilar" under the Inflation Reduction Act receives reimbursement equal to the biosimilar's Average Sales Price (ASP) plus 8% of the reference product's ASP. This ASP+8% mechanism creates a margin incentive for providers to prescribe biosimilars over the reference biologic — a structural nudge that did not exist under earlier reimbursement models.

The competitive dynamics vary by molecule. Markets with multiple biosimilar entrants have experienced steeper price erosion than categories with only one or two biosimilar competitors. For BD teams, the number of biosimilar competitors in a given therapeutic class is a critical variable in forecasting originator revenue erosion and identifying acquisition or partnership targets. The BsUFA user fee legislation further supports the review infrastructure that enables this accelerating approval pipeline.

Internationally, the regulatory framework provides additional context. The EMA's biosimilar information guide for healthcare professionals outlines the European experience with biosimilar adoption, where earlier market entry and more aggressive tendering mechanisms have produced higher uptake rates than the U.S. market has achieved to date.

What Are the Strategic Implications for BD Teams and Investors?

The biosimilar wave creates asymmetric risk and opportunity across the pharmaceutical value chain. For originator companies facing biosimilar entry, the strategic playbook includes authorized biosimilar launches, indication lifecycle management, and pricing rebate strategies designed to retain formulary positioning. The adalimumab experience offers a template: originators that engaged payers early with competitive contracting preserved more market share than those that relied on rebate walls alone.

For biosimilar manufacturers, the opportunity set is expanding. The current pipeline spans oncology, immunology, ophthalmology, and endocrinology — therapeutic areas where reference biologics generate billions in annual revenue. Companies with manufacturing scale, regulatory expertise, and established commercial infrastructure in specialty pharmacy distribution are best positioned to capture share.

Investors should monitor three metrics as indicators of biosimilar market maturation: (1) the ratio of biosimilar-to-originator ASP, which signals pricing pressure intensity; (2) formulary coverage rates among top PBMs, which reflects payer confidence; and (3) switching rates in claims data, which captures real-world adoption behavior. Together, these variables provide an early-warning framework for portfolio exposure to biosimilar competition.

R&D investment decisions are also shifting. As biosimilar competition compresses returns on me-too biologics, originator companies are redirecting pipeline capital toward modalities — cell therapy, gene therapy, RNA-based therapeutics — where biosimilar substitution is structurally more difficult. This reallocation has implications for the long-term competitive dynamics of the biologics market and the therapeutic areas where biosimilar-driven savings will be most concentrated.

Frequently Asked Questions

Related coverage

• Fulcrum Explores Sale Amid FDA Setback for Sickle Cell Drug
• FDA Declines Cingulate's ADHD Drug CTx-1301 Over Manufacturing Concerns
• Experimental pancreatic cancer drug offers new hope in major trial